H22 subcutaneous tumor-bearing mice were treated with anti-PD-L1 (5 mg/kg every 3 days) or anti-PD-L1 (2.5 mg/kg every 3 days) combined with emodin (50 mg/kg/daily), as displayed in Fig. 7F. We observed no significant difference in body weight among the control, anti-PD-L1, and emodin plus anti-PD-L1 groups (Fig. 7G). This evidence concerns the gene CD274 and neoplasm.